Core Insights - Revenue grew 105% year-over-year to $2.2 million, driven by expanded adoption of the first-generation LungFit PH system across more than 45 hospitals [1] - Customer retention exceeds 90% with over half of the current customer base secured under multiyear agreements, providing a stable foundation for future Gen II conversion [1] - The commercial strategy has shifted toward high-priority hospitals that are likely to adopt Gen I immediately and expand usage once the transport-compatible Gen II system is approved [1] Financial Performance - Operating expenses were reduced by 36% year-over-year, reflecting disciplined cost-cutting in SG&A and the completion of major R&D spending for the Gen II regulatory filing [1] Strategic Moves - The divestiture of the NeuroNOS subsidiary to XTL Biopharmaceuticals allows the company to focus resources on core commercial operations while retaining a 19.9% equity stake and up to $31.5 million in milestones [1] - International expansion reached 40 countries, with management noting a transition from initial device placement to recurring revenue from accessory reorders [1]

Core Viewpoint - XTL Biopharmaceuticals Ltd. is actively working to finalize the acquisition of 85% of NeuroNOS Ltd. from Beyond Air Inc. and has scheduled a shareholders meeting to approve a private placement of up to US$2 million [1][2]. Group 1: Acquisition and Financial Strategy - The company has executed a Binding Letter of Intent on January 13, 2026, for the acquisition of NeuroNOS Ltd. [1] - The completion of this acquisition and the private placement is expected to address the company's deficiency under Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2,500,000 in stockholders' equity [2]. - A shareholders meeting is set for February 17, 2026, to approve the private placement [1]. Group 2: Company Overview - XTL Biopharmaceuticals Ltd. holds 100% of The Social Proxy Ltd. and has an intellectual property portfolio that includes hCDR1 for Lupus (SLE) and Sjögren's Syndrome (SS) [3]. - The company is focused on strategic collaborations and acquisitions to enhance its therapeutic portfolio in high-value disease areas [3]. - XTL trades on the Nasdaq Capital Market and the Tel Aviv Stock Exchange [3].

Core Viewpoint - XTL Biopharmaceuticals Ltd. has received a notification from Nasdaq indicating that it does not meet the continued listing requirement of maintaining a minimum of $2,500,000 in stockholders' equity, reporting a deficit of $47,000 as of June 30, 2025 [1][2]. Group 1: Nasdaq Notification - The notification does not lead to immediate delisting of the Company's American Depositary Shares (ADSs), which will continue to trade under the symbol "XTLB" [2]. - The Company has 45 calendar days, until March 6, 2026, to submit a plan to regain compliance, with the possibility of an extension of up to 180 days if the plan is accepted [2]. Group 2: Compliance Efforts - XTL is currently evaluating options to regain compliance with Nasdaq's continued listing requirements and intends to make reasonable efforts to achieve this [3]. - There is no assurance that the Company will successfully regain compliance with the listing requirements [3]. Group 3: Company Overview - XTL Biopharmaceuticals Ltd. is an IP Portfolio company that holds 100% of The Social Proxy Ltd. and has an IP portfolio including hCDR1 for Lupus (SLE) and Sjögren's Syndrome (SS) [4]. - The Company actively seeks strategic collaborations and acquisitions to expand its therapeutic portfolio into high-value disease areas [4].

Market Performance - U.S. stocks showed mixed performance with the Dow Jones index falling over 200 points, down 0.60% to 49,293.33, while the NASDAQ gained 0.17% to 23,773.29 and the S&P 500 dropped 0.08% to 6,971.95 [1] - In the energy sector, shares increased by 1.4%, while financial stocks decreased by 1.8% [1] Inflation Data - Inflation remained steady in December, with the Consumer Price Index rising 2.7% year over year, matching economist expectations and unchanged from November [2] - Monthly consumer prices increased by 0.3%, also in line with forecasts [2] Commodity Prices - Oil prices rose by 2.6% to $61.06, while gold increased by 0.1% to $4,620.80 [4] - Silver prices surged by 4.4% to $88.860, whereas copper fell by 0.1% to $6.0295 [4] European Market Trends - European shares were mixed, with the eurozone's STOXX 600 falling 0.08% and Spain's IBEX 35 Index rising 0.08% [5] - London's FTSE 100 slipped 0.03%, Germany's DAX gained 0.06%, and France's CAC 40 fell 0.14% [5] Asian Market Performance - Asian markets closed mixed, with Japan's Nikkei surging 3.10% and Hong Kong's Hang Seng Index gaining 0.90% [8] - Conversely, China's Shanghai Composite fell 0.64% and India's BSE Sensex decreased by 0.30% [8] Company-Specific Movements - Beyond Air Inc shares surged 172% to $2.39 following an acquisition agreement, potentially receiving up to $32.5 million [7] - Ambitions Enterprise Management Co LLC shares increased by 106% to $10.90 due to a year-over-year EPS increase [7] - TryHard Holdings Ltd shares rose by 77% to $40.96 after announcing a collaboration agreement and a $10 million share repurchase program [7] - Signing Day Sports Inc shares dropped 57% to $0.25 after announcing a public offering [7] - Travere Therapeutics Inc shares fell 32% to $23.16 following preliminary fourth-quarter financial results [7] - Wealthfront Corp shares decreased by 18% to $10.34 due to weak quarterly sales [7]

Market Performance - U.S. stocks showed mixed trading results, with the Dow Jones index falling over 200 points, down 0.60% to 49,293.33, while the NASDAQ gained 0.17% to 23,773.29, and the S&P 500 dropped 0.08% to 6,971.95 [1] - Energy shares increased by 1.4%, while financial stocks decreased by 1.8% [1] Inflation Data - Inflation remained steady in December, with the Consumer Price Index rising 2.7% year over year, unchanged from November and matching economist expectations [2] - Monthly consumer prices increased by 0.3%, also in line with forecasts [2] Commodity Prices - Oil prices rose by 2.6% to $61.06, while gold increased by 0.1% to $4,620.80 [4] - Silver prices surged by 4.4% to $88.860, whereas copper fell by 0.1% to $6.0295 [4] European Market Performance - European shares were mixed, with the eurozone's STOXX 600 falling 0.08%, while Spain's IBEX 35 Index rose 0.08% [5] - London's FTSE 100 slipped 0.03%, Germany's DAX gained 0.06%, and France's CAC 40 fell 0.14% [5] Asian Market Performance - Asian markets closed mixed, with Japan's Nikkei surging 3.10% and Hong Kong's Hang Seng Index gaining 0.90% [8] - Conversely, China's Shanghai Composite fell 0.64% and India's BSE Sensex decreased by 0.30% [8] Company-Specific Movements - Beyond Air Inc shares surged 172% to $2.39 following an acquisition agreement, potentially receiving up to $32.5 million [7] - Ambitions Enterprise Management Co LLC shares increased by 106% to $10.90 due to a year-over-year EPS increase [7] - TryHard Holdings Ltd shares rose by 77% to $40.96 after announcing a collaboration agreement and a $10 million share repurchase program [7] - Signing Day Sports Inc shares dropped 57% to $0.25 after announcing a public offering [7] - Travere Therapeutics Inc shares fell 32% to $23.16 following preliminary fourth-quarter financial results [7] - Wealthfront Corp shares decreased by 18% to $10.34 due to weak quarterly sales [7]

Market Overview - U.S. stocks traded lower, with the Dow Jones index falling more than 300 points, down 0.66% to 49,264.22, NASDAQ down 0.15% to 23,699.14, and S&P 500 down 0.24% to 6,960.41 [1] - Financial stocks dipped by 1.7% on Tuesday [2] - Energy shares gained by 1.4% [1] Company Earnings - JPMorgan Chase & Co reported better-than-expected earnings for Q4, with earnings of $5.23 per share, surpassing the analyst consensus estimate of $4.92 per share. Quarterly sales were $46.767 billion, exceeding the consensus estimate of $46.024 billion [3] Commodity Market - Oil traded up 2% to $60.69, while gold traded down 0.5% at $4,592.90. Silver rose 0.7% to $85.700, and copper increased by 0.4% to $6.0545 [5] International Markets - European shares were mostly lower, with the eurozone's STOXX 600 down 0.1%, Spain's IBEX 35 down 0.2%, London's FTSE 100 down 0.1%, Germany's DAX down 0.1%, and France's CAC 40 down 0.4% [6] - Asian markets closed mixed, with Japan's Nikkei up 3.10%, Hong Kong's Hang Seng Index up 0.90%, while China's Shanghai Composite fell 0.64% and India's BSE Sensex fell 0.30% [7] Stock Movements - Beyond Air Inc shares surged 153% to $2.22 after XTL Biopharmaceuticals agreed to acquire an 85% stake in its NeuroNOS subsidiary, with potential payments up to $32.5 million [9] - Ambitions Enterprise Management Co LLC shares increased by 105% to $10.80 following a year-over-year increase in H1 EPS results [9] - AlphaTON Capital Corp shares rose 81% to $1.65 [9] - Signing Day Sports Inc shares dropped 55% to $0.26 after announcing a $5.6 million public offering [9] - Rich Sparkle Holdings Ltd shares fell 27% to $68.16, and Mingteng International Corp Inc shares decreased by 29% to $0.054 [9] Economic Indicators - The NFIB Small Business Optimism Index surged to 99.5 in December, marking its highest level since August [8] - The annual inflation rate remained at 2.7% in December, unchanged from the previous month [10]

Core Insights - XTL Biopharmaceuticals Ltd. has announced a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc., which focuses on disease-modifying therapeutics for Autism Spectrum Disorder (ASD) and neuro-oncology [1][2] - The acquisition positions XTL as a significant player in the autism therapeutics market, addressing a critical unmet medical need as 1 in 31 U.S. children are affected by autism, with no FDA-approved disease-modifying therapies currently available [3][4] Company Overview - NeuroNOS was founded by Professor Haitham Amal, a leading autism researcher, and has strengthened its scientific leadership by adding two Nobel Laureates in Chemistry, enhancing its potential for therapeutic innovation [5][7] - The company’s drug development platform targets the underlying molecular mechanisms of autism through a proprietary family of small molecules that can cross the blood-brain barrier [8] Market Opportunity - The autism crisis has led to increased strain on healthcare systems and families, with a significant rise in cases prompting urgent calls for new therapeutic pathways and research funding from U.S. policymakers [3][4] - The U.S. government has allocated $50 million in new NIH funding for autism research initiatives, indicating a shift in regulatory priorities towards autism treatment development [4] Transaction Details - XTL will acquire 85% of NeuroNOS for a combination of cash, shares, and milestone payments totaling up to $32.5 million, with the transaction subject to shareholder approval [10][11] - The milestone payments include up to $5.5 million for clinical development and up to $26 million for achieving product sales targets [11] Scientific Validation - NeuroNOS has secured FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma, which provide market exclusivity and expedited regulatory review upon approval [9] - Preclinical studies have shown that the platform addresses core pathological mechanisms in autism, validating nitric oxide dysregulation as a therapeutic target [8]

Core Insights - XTL Biopharmaceuticals Ltd. has announced a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc., which focuses on disease-modifying therapeutics for Autism Spectrum Disorder (ASD) and neuro-oncology [1][2] - The acquisition positions XTL as a significant player in the autism therapeutics market, addressing a critical unmet medical need as 1 in 31 U.S. children are affected by autism, with no FDA-approved disease-modifying therapies currently available [3][4] Company Overview - NeuroNOS was founded by Professor Haitham Amal, a leading autism researcher, and has strengthened its scientific leadership by adding two Nobel Laureates in Chemistry, enhancing its potential for therapeutic innovation [5][7] - The company’s drug development platform targets the underlying molecular mechanisms of autism through a proprietary family of small molecules that can cross the blood-brain barrier [8] Market Opportunity - The autism crisis has led to increased strain on healthcare systems and families, with a significant rise in cases prompting urgent calls for new therapeutic pathways and research funding from U.S. policymakers [3][4] - The U.S. government has allocated $50 million in new NIH funding for autism research initiatives, indicating a shift in regulatory priorities towards autism treatment development [4] FDA Designations and Financial Terms - NeuroNOS has secured FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma, which provide market exclusivity and expedited regulatory review [9] - The transaction terms include XTL acquiring 85% of NeuroNOS for 19.9% of XTL's issued share capital, $1 million in cash, and milestone payments up to $32.5 million [10][11] Strategic Commitment - Both XTL and Beyond Air are committed to advancing NeuroNOS's autism treatment programs with urgency, aiming to bring innovative therapies to market [11][12] - The acquisition is seen as a pivotal moment for NeuroNOS, providing the necessary focus and funding to advance its pipeline in autism and neuro-oncology [12]

Core Viewpoint - AbCellera Biologics Inc. reported a quarterly loss of $0.12 per share, outperforming the Zacks Consensus Estimate of a loss of $0.17, indicating a positive earnings surprise of +29.41% [1] Financial Performance - The company posted revenues of $17.08 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 146.95%, compared to $7.32 million in the same quarter last year [2] - Over the last four quarters, AbCellera has surpassed consensus EPS estimates three times [2] Stock Performance - AbCellera shares have increased approximately 40.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] Future Outlook - The company's earnings outlook will be crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.17 on revenues of $7.31 million, and for the current fiscal year, it is -$0.69 on revenues of $25.53 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which AbCellera belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Insights - The FDA has granted Orphan Drug Designation (ODD) to NeuroNOS's lead investigational therapy, BA-102, for treating Phelan-McDermid Syndrome (PMS), a condition associated with Autism Spectrum Disorder (ASD) [1][3] - NeuroNOS plans to initiate first-in-human clinical trials for ASD in the U.S. in 2026 [1] Company Overview - NeuroNOS is a biopharmaceutical company focused on developing treatments for autism and Alzheimer disorders, and is a subsidiary of Beyond Air [1][5] - The company specializes in therapies based on small molecules that can cross the blood-brain barrier to regulate Nitric Oxide (NO) levels in the brain [5] Disease Background - Phelan-McDermid Syndrome (PMS) is a rare genetic disorder primarily caused by deletions or mutations affecting the SHANK3 gene, leading to symptoms such as global developmental delay, intellectual disability, and severe speech impairments [2][4] - There are currently no FDA-approved treatments specifically indicated for PMS [2] Development Incentives - The ODD provides several key development incentives, including seven years of market exclusivity upon approval, tax credits for qualified clinical trials, waiver of FDA application fees, and access to FDA protocol assistance [3] Commitment to Development - NeuroNOS is committed to collaborating with the FDA, patient advocacy groups, scientific foundations, and clinical investigators to accelerate the development of therapies for PMS [4]